Table 2.
Anti-TNF biosimilar products that are currently authorised in the EU and US.
| Anti-TNF | Reference medicinal product | Patent Expiry EU (US) | Approved Biosimilar products |
|
|---|---|---|---|---|
| EU | US | |||
| Infliximab | Remicade® (Janssen) | 2015 (2018) | Remsima®/Inflectra® (Celltrion/Hospira2, Sep 2013), Flixabi® (Samsung Bioepis, May 2016) Zessly® (Sandoz, May 2018) | Inflectra®(Celltrion/Hospira2, Apr 2016), Renflexis® (Samsung Bioepis, May 2017), Ixifi® (Pfizer, Dec 2017) |
| Etanercept | Enbrel® (Amgen/Pfizer) | 2015 (2028) | Benepali (Samsung Bioepis, Jan 2016), Erelzi (Sandoz, June 2017) | Erelzi (Sandoz, Aug 2016) |
| Adalimumab | Humira® (Abbvie) | 2018 (2016) |
1Amgevita® (Amgen, Mar 2017), 1Solymbic® (Amgen, Mar 2017), Imraldi® (Samsung Bioepis, Aug 2017), Cyltezo® (Boehringer Ingelheim, Nov 2017) |
Amjevita® (Amgen, Sep 2016), Cyltezo® (Boehringer Ingelheim, Aug 2017) |
1Duplicate marketing authorization; 2Now acquired by Pfizer